Iron polymaltose

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Iron polymaltose
DrugBank Accession Number
DB15763
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 449.163
Monoisotopic: 449.059366
Chemical Formula
C12H25FeO14
Synonyms
  • Ferric hydroxide polymaltose complex
  • Ferromaltose
  • Iron polymaltose
  • Iron polymaltose complex
  • Iron(III)-hydroxide polymaltose complex

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Alendronic acidIron polymaltose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlmasilateAlmasilate can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsenapineAsenapine can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium PhosphateIron polymaltose can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrateIron polymaltose can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CarbidopaIron polymaltose can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
CefdinirIron polymaltose can cause a decrease in the absorption of Cefdinir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Amylofer / Ferinject / Ferripel 3 / Ferripel-3 / Injectafer / Maltofer / Teferrol
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
EUROFER® -iron syrupSyrupOralEURODRUG LABORATORIES (M) SDN BHD2020-09-08Not applicableMalaysia flag
MALTOFERSyrup50 mg/5mlOralบริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด2009-04-23Not applicableThailand flag
Saferon Drops 50mg/mlSolution / dropsOralGlenmark Pharmaceuticals (Malaysia) Sdn. Bhd.2020-09-08Not applicableMalaysia flag
Saferon SyrupSyrupOralGlenmark Pharmaceuticals (Malaysia) Sdn. Bhd.2020-09-08Not applicableMalaysia flag
Trifer Drops 50mg/mlSolution / dropsOralUNIMED SDN BHD2020-09-08Not applicableMalaysia flag
ยูโรเฟอร์-ไอเอินSyrup50 mg/5mlOralบริษัท โอสถ อินเตอร์ แลบบอราทอรีส์ จำกัด2006-08-25Not applicableThailand flag
เฟอร์โรซอล พีเอ็ม ดร๊อปSyrup50 mg/5mlOralห้างหุ้นส่วนจำกัด โรงงานเลิศสิงห์เภสัชกรรม2016-09-20Not applicableThailand flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
CHALVER HEMATIN FOL®Iron polymaltose (1 g) + Folic acid (4000 mcg)SyrupOralLABORATORIOS CHALVER DE COLOMBIA S.A.2006-11-10Not applicableColombia flag
CHALVER-HEMATIN�PLUS GOTASIron polymaltose (50 mg) + Nicotinamide (25 mg) + Pyridoxine hydrochloride (2.5 mg) + Riboflavin sodium (2.5 mg) + Thiamine hydrochloride (2.5 mg)SolutionOralLABORATORIOS CHALVER DE COLOMBIA S.A.2006-11-10Not applicableColombia flag
HEMATIN PLUS JARABEIron polymaltose (1 g) + Nicotinamide (0.5 g) + Pyridoxine (50 mg) + Riboflavin sodium (50 mg) + Thiamine hydrochloride (50 mg)SyrupOralLABORATORIOS CHALVER DE COLOMBIA S.A.2006-11-10Not applicableColombia flag
HERREX FOL� JARABEIron polymaltose (1 g) + Folic acid (2.4 mg)SyrupOralALTEA FARMACEUTICA S.A.2006-11-10Not applicableColombia flag
HERREX� FOL 1000 TABLETAS RECUBIERTASIron polymaltose (100 mg) + Folic acid (1 mg)Tablet, coatedOralALTEA FARMACEUTICA S.A.2007-10-03Not applicableColombia flag
IROFAS SyrupIron polymaltose (50 mg/5ml) + Ascorbic acid (100 mg/5ml) + Folic acid (2 mg/5ml)SyrupOralHEALOL PHARMACEUTICALS SDN. BHD.2020-09-08Not applicableMalaysia flag
MALTOFER FOLIron polymaltose (100 MG) + Folic acid (0.35 MG)Tablet, chewableOralบริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด2009-04-23Not applicableThailand flag
MALTOFER FOLIron polymaltose (100 MG) + Folic acid (0.35 MG)Tablet, chewableOralบริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด2009-04-232020-09-01Thailand flag
OROFER CAPSULESIron polymaltose (100 MG) + Folic acid (0.55 MG)Capsuleบริษัท อัลลายแอนซ์ ฟาร์มา จำกัด2015-01-13Not applicableThailand flag
Saferon Chewable TabletIron polymaltose (100 mg) + Folic acid (500 mcg)Tablet, chewableOralGlenmark Pharmaceuticals (Malaysia) Sdn. Bhd.2020-09-08Not applicableMalaysia flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
UM5219H89V
CAS number
53858-86-9
InChI Key
PKMVWNYIYVZXIQ-MPAYLTKRSA-K
InChI
InChI=1S/C12H22O11.Fe.3H2O/c13-1-4(15)7(17)8(18)5(16)3-22-12-11(21)10(20)9(19)6(2-14)23-12;;;;/h1,4-12,14-21H,2-3H2;;3*1H2/q;+3;;;/p-3/t4-,5+,6+,7+,8+,9+,10-,11+,12-;;;;/m0..../s1
IUPAC Name
iron(3+) (2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexanal trihydroxide
SMILES
[OH-].[OH-].[OH-].[Fe+3].OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]1O

References

General References
Not Available
ChemSpider
32701213
RxNav
37744
Wikipedia
Iron_polymaltose

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentEndothelial Dysfunction / Iron Toxicity / Oxidative Stress / Renal Anemia1
4CompletedTreatmentAnemia / Gastrointestinal Hemorrhage1
4CompletedTreatmentAnemia / Heart Failure / Iron Deficiency (ID)1
4CompletedTreatmentAnemia / Iron Deficiency (ID)2
4CompletedTreatmentAnemia / Neoplasms, Colorectal1
4CompletedTreatmentChronic Heart Failure (CHF) / Iron Deficiency (ID)2
4CompletedTreatmentChronic Plaque Psoriasis1
4CompletedTreatmentFatigue1
4CompletedTreatmentHeart Failure / Iron Deficiency (ID)1
4CompletedTreatmentHeart Failure / Iron Deficiency (ID) / Iron-Deficiency1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral
SyrupOral
SolutionOral100 mg/5ml
SyrupOral50 mg/5ml
Tablet, film coatedOral101 mg
SolutionIntravenous
SolutionOral
Granule, effervescentOral
CapsuleOral
PowderOral
SolutionOral50 mg
SyrupOral1 g
Tablet, coatedOral
Injection, solutionIntramuscular
SyrupOral
Capsule
Tablet, chewableOral
InjectionIntramuscular
TabletOral
Solution / dropsOral
Tablet, film coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility229.0 mg/mLALOGPS
logP-2.8ALOGPS
logP-5.3ChemAxon
logS-0.17ALOGPS
pKa (Strongest Acidic)11.93ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area197.37 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity69.76 m3·mol-1ChemAxon
Polarizability31.4 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on August 19, 2020 22:26 / Updated on August 21, 2020 19:35